Tempus AI (NASDAQ:TEM) Trading Down 7.8% – Here’s Why

Tempus AI, Inc. (NASDAQ:TEM)’s stock price was down 7.8% during trading on Tuesday . The stock traded as low as $82.62 and last traded at $82.47. Approximately 11,643,962 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 13,738,480 shares. The stock had previously closed at $89.44.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TEM shares. Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a research report on Tuesday, January 14th. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Piper Sandler reissued a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.55.

Tempus AI Price Performance

The firm’s fifty day moving average price is $47.46 and its 200-day moving average price is $50.72. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insiders Place Their Bets

In other news, CEO Eric P. Lefkofsky sold 187,655 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the completion of the sale, the chief executive officer now owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. This trade represents a 1.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the transaction, the insider now owns 15,218,365 shares in the company, valued at $534,164,611.50. The trade was a 1.71 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,401,779 shares of company stock valued at $115,707,361.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Operose Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $25,000. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter worth approximately $30,000. Farther Finance Advisors LLC bought a new position in Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC increased its holdings in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after buying an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth approximately $49,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.